Recital 31, Regulation (EU) 2026/2348

In force

The application for the renewal of the approval of the active substance halosulfuron-methyl was submitted on 28 September 2020 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 10 December 2020 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 8 March 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 14 July and 12 September 2023. On 20 November 2023, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 5 January 2024 within the deadline given. On 23 May 2025, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance halosulfuron-methyl in the Standing Committee on 9 July 2025. The draft renewal report were first discussed in the Standing Committee on 24 September 2026. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 9 months, until 15 August 2027.

  • celex=32012R0844